DUBLIN, Nov. 9, 2017 /PRNewswire/ -- Jazz
Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company
will be webcasting its corporate presentations at three upcoming
investor conferences.
- Jefferies London Healthcare Conference in London on Thursday,
November 16, 2017 at 8:40 a.m.
GMT / 3:40 a.m. EST.
Iain McGill, senior vice president, Jazz Pharmaceuticals
Europe and rest of world, will provide an overview of the company
and a business and financial update.
- Piper Jaffray 29th
Annual Healthcare Conference in New York,
NY on Tuesday, November 28,
2017 at 8:00 a.m. EST /
1:00 p.m. GMT. Bruce Cozadd, chairman and chief executive
officer, will provide an overview of the company and a business and
financial update.
- Evercore ISI Biopharma Conference in Boston, MA on Wednesday, November 29, 2017 at 10:15 a.m. EST / 3:15 p.m.
GMT. Bruce Cozadd,
chairman and chief executive officer, will provide an overview of
the company and a business and financial update.
A live audio webcast of each presentation may be accessed from
the Investors section of the Jazz Pharmaceuticals website at
www.jazzpharmaceuticals.com. Please connect to the website
prior to the start of the presentation to ensure adequate time for
any software downloads that may be necessary to listen to the
webcast.
An archive of the webcast will be available for at least one
week following the presentation on the Investors section of the
company's website at www.jazzpharmaceuticals.com.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is an international
biopharmaceutical company focused on improving patients' lives by
identifying, developing and commercializing meaningful products
that address unmet medical needs. The company has a diverse
portfolio of products and product candidates with a focus in the
areas of sleep and hematology/oncology. In these areas, Jazz
Pharmaceuticals markets Xyrem® (sodium oxybate) oral solution,
Erwinaze® (asparaginase Erwinia chrysanthemi), Defitelio®
(defibrotide sodium) and Vyxeos™ (daunorubicin and cytarabine)
liposome for injection in the U.S. and markets Erwinase® and
Defitelio® (defibrotide) in countries outside the U.S. For
more information, please visit www.jazzpharmaceuticals.com.
Logo -
https://mma.prnewswire.com/media/600128/Jazz_Pharmaceuticals_Logo.jpg